Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study

Mehik, Aare; Alas, Peeter; Nickel, J. Curtis; Sarpola, Ari; Helström, Pekka J.

doi:10.1016/s0090-4295(03)00466-7

Cited by 142 publications

(75 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, as the clinical effect of a-blocker was modest, it cannot be recommended as a monotherapy. [5][6][7] Magnetic stimulation has been developed for the noninvasive stimulation of the central and peripheral nervous system. 8 It is the nerves that are most sensitive to electrical depolarization by a changing magnetic field.…”

Section: Introductionmentioning

confidence: 99%

More effects of extracorporeal magnetic innervation and terazosin therapy than terazosin therapy alone for non-inflammatory chronic pelvic pain syndrome: a pilot study

Paick

2006

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The objective of this study was to evaluate whether extracorporeal magnetic innervation (ExMI) combined with a-blocker therapy is more effective than a-blocker monotherapy for patients with non-inflammatory chronic prostatitis (CP)/chronic pelvic pain syndrome (CPPS), category IIIB. Patients were randomized to either terazosin monotherapy (group 1, n ¼ 21) or terazosin combined with ExMI therapy (group 2, n ¼ 19). Patients in group 2 had 12 treatment sessions of ExMI twice a week during 6 weeks. None of the patients experienced any side effects from treatment. The changes in each domain of the National Institutes of Health (NIH)-Chronic Prostatitis Symptom Index (CPSI) measured on week 6 were not significantly different between the groups. However, the difference (median, 25-75th percentiles) between the two groups in total NIH-CPSI scores was À4 (À11.5, À2) for group 1 and À12 (À17.3, À2.3) for group 2, respectively (P ¼ 0.047). At 6 weeks, 47.6% (10 of 21) of group 1 had a 425% decrease in total NIH-CPSI compared with 78.9% (15 of 19) of group 2 (P ¼ 0.041). Also, more patients in group 2 (78.9%) were rated as responders with a 6-point decrease in NIH-CPSI compared with group 1 (47.6%) (P ¼ 0.041). The early results suggest that ExMI combined with a-blocker therapy has better effect than a-blocker monotherapy for the treatment of CP/CPPS.

show abstract

Section: Introductionmentioning

confidence: 99%

More effects of extracorporeal magnetic innervation and terazosin therapy than terazosin therapy alone for non-inflammatory chronic pelvic pain syndrome: a pilot study

Paick

2006

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…Three randomised, placebo-controlled trials evaluating tamsulosin [14], terazosin [12] and alfuzosin [13] showed a statistically and likely clinically significant treatment effect with these alpha-blockers. However, a well powered, NIH Chronic Prostatitis Collaborative Research Network (CPCRN) trial of 6 weeks of the alpha-blocker tamsulosin appears to provide no additional benefit to placebo when used in CP/CPPS patients who have had the condition longterm and who had been heavily pre-treated (including previous treatment with alpha-blockers) [13].…”

Section: Alpha-blockersmentioning

confidence: 99%

“…However, a well powered, NIH Chronic Prostatitis Collaborative Research Network (CPCRN) trial of 6 weeks of the alpha-blocker tamsulosin appears to provide no additional benefit to placebo when used in CP/CPPS patients who have had the condition longterm and who had been heavily pre-treated (including previous treatment with alpha-blockers) [13]. An analysis of these four trials would indicate that longer courses (more than 6 weeks) of alpha-blockers provide modest benefits when prescribed to alpha-blocker-naïve CP/CPPS patients with shorter duration of disease.…”

Section: Alpha-blockersmentioning

confidence: 99%

Treatment of chronic prostatitis/chronic pelvic pain syndrome

Nickel

2008

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

Acceptance of the National Institutes of Health definition of Category III Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) and the development and validation of the Chronic Prostatitis Symptom Index has stimulated significant research into treatment of this condition. Evidence-based suggestions for treatment include the following. (i) Antimicrobials cannot be recommended for men with longstanding, previously treated CP/CPPS. (ii) Alpha-blockers can be recommended as firstline medical therapy, particularly in alpha-blocker-naïve men with moderately severe symptoms who have relatively recent onset of symptoms. (iii) Alpha-blockers cannot be recommended in men with longstanding CP/CPPS who have tried and failed alpha-blockers in the past. And (iv) antiinflammatory therapy, finasteride and pentosan polysulfate are not recommended as primary treatment; however, they may have a useful adjunctive role in a multimodal therapeutic regimen. Early data on herbal therapies, particularly quercetin and cernilton, are intriguing, but larger multicentre, randomised, placebo-controlled trials are required before a high level of evidence recommendation can be made on its use. At this time, surgery (including minimally invasive) is recommended only for definitive indications and not generally for CP/CPPS.

show abstract

“…Özellikle kategori IIIB'de etkisi olan alfa blokerlerin verilmesi ile çıkım obstrüksiyonun düzeleceği, idrar akımının kolaylaşacağı ve intraprostatik duktal reflünün oluşmayacağı düşünülebilir. KPAS'da alfa blokerlerin etkinliği % 50 civarındadır ve en az 3 ay tedavi sürdürülmelidir 14,30 .Alfa blokerlerin etkinliği ile ilgili yapılan randomize plasebo kontrollü çalışmalarda tamsulosin, alfuzosin ve terazosinin istatistiksel ve klinik olarak anlamlı terapötik etkisinin olduğu bildirilmiştir 18,31,32 .…”

Section: Kronik Nonbakteriyel Prostatit / Kronik Pelvik Ağrı Sendromuunclassified

Kronik Prostatit/Kronik Pelvik Ağrı Sendromu Tanı ve Tedavisi

Yücetürk¹,

Özgür²,

Sarıcı³

2014

Arşiv Kaynak Tarama Dergisi

View full text Add to dashboard Cite

Chronic prostatitis is a chronic syndrome that effects men with a wide range of age. The etiology,natural history and appropriate therapy models are still unclear. According to the classification of National Institutes of Health 4 types of prostatitis were defined. Acute bacterial prostatitis (category I), chronic bacterial prostatitis (category II), chronic nonbacterial prostatitis/chronic pelvic pain syndrome (category III) and asymptomatic prostatitis (category IV). Quality of life in patients with chronic prostatitis is effected seriously. Because microorganisms can only be isolated from less percent of patients, empiric treatment is given to the most of the men. Multidisciplinary approach to the patients with suspected chronic prostatitis will help clinicians to play an active role in the treatment and prevent unnecessary medical therapies.

show abstract

Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study

Cited by 142 publications

References 16 publications

More effects of extracorporeal magnetic innervation and terazosin therapy than terazosin therapy alone for non-inflammatory chronic pelvic pain syndrome: a pilot study

More effects of extracorporeal magnetic innervation and terazosin therapy than terazosin therapy alone for non-inflammatory chronic pelvic pain syndrome: a pilot study

Treatment of chronic prostatitis/chronic pelvic pain syndrome

Kronik Prostatit/Kronik Pelvik Ağrı Sendromu Tanı ve Tedavisi

Contact Info

Product

Resources

About